Northern Trust
ANTX icon

Northern Trust’s AN2 Therapeutics ANTX Stock Holding History

Northern Trust’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Hold
43,196
– – ﹤0.01% 4021
2025
Q4 		$49.2K Hold
43,196
– – ﹤0.01% 4280
2025
Q3 		$54.9K Hold
43,196
– – ﹤0.01% 4269
2025
Q2 		$45.8K Hold
43,196
– – ﹤0.01% 4245
2025
Q1 		$58.7K Hold
43,196
– – ﹤0.01% 4209
2024
Q4 		$59.6K Buy
43,196
+10,601
+33% +$12.9K ﹤0.01% 4241
2024
Q3 		$34.9K Hold
32,595
– – ﹤0.01% 4268
2024
Q2 		$70.1K Sell
32,595
-3,768
-10% -$8.97K ﹤0.01% 4136
2024
Q1 		$118K Buy
36,363
+3,313
+10% +$36K ﹤0.01% 4033
2023
Q4 		$677K Buy
33,050
+16,415
+99% +$275K ﹤0.01% 3442
2023
Q3 		$267K Buy
+16,635
New +$188K ﹤0.01% 3710
2023
Q2 		– Sell
-76,134
Closed -$751K – 4535
2023
Q1 		$751K Sell
76,134
-4,684
-6% -$52.1K ﹤0.01% 3314
2022
Q4 		$770K Buy
80,818
+43,379
+116% +$581K ﹤0.01% 3355
2022
Q3 		$650K Buy
37,439
+1,042
+3% +$12.1K ﹤0.01% 3427
2022
Q2 		$282K Buy
+36,397
New +$482K ﹤0.01% 3750

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Northern Trust's ANTX Position: Q1 2026 in Review

Northern Trust held its AN2 Therapeutics (ANTX) position steady in Q1 2026 at 43,196 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #4021.

Northern Trust first reported a position in ANTX in Q2 2022 and has held it in 15 quarters since. The position peaked at $770K in Q4 2022. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Northern Trust held 43,196 shares of AN2 Therapeutics worth $148K as of Q1 2026.
  • Northern Trust left its AN2 Therapeutics share count unchanged in Q1 2026.
  • AN2 Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4021 holding.
  • Northern Trust first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • Northern Trust's AN2 Therapeutics position peaked at $770K in Q4 2022.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.